Lookup NU author(s): Professor John Isaacs
This is the final published version of an article that has been published in its final definitive form by Oxford University Press, 2017.
For re-use rights please refer to the publisher's terms and conditions.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. Objective. The aim was to correlate protein concentrations of S100A9 in pretreatment serum samples with response to the tumour-necrosis factor (TNF) inhibitor drugs etanercept in a large UK replication cohort. Methods. Pretreatment serum samples from patients with RA (n = 236) about to commence treatment with etanercept had S100A9 serum concentration measured using an ELISA. Following the experimental procedure, S100A9 concentrations were analysed with respect to EULAR response. Results. No evidence of association between S100A9 concentration and EULAR response to the TNFinhibitor biologic drug etanercept was observed following multinomial logistic regression analysis (nonresponder vs moderate responder, P = 0.957; and non-responder vs good responder, P = 0.316). Furthermore, no significant associations were observed when correlating pretreatment S100A9 concentrations with clinical parameters of disease activity (P> 0.05). Conclusion. In the largest replication cohort conducted to date, no evidence for association was observed to support the use of S100A9 as a clinical biomarker predictive of response to the TNF-inhibitor biologic drug etanercept.
Author(s): Smith SL, Plant D, Eyre S, Hyrich K, Morgan AW, Wilson AG, Isaacs JD, Barton A
Publication type: Article
Publication status: Published
Print publication date: 01/06/2017
Online publication date: 16/01/2017
Acceptance date: 22/09/2016
Date deposited: 13/07/2017
ISSN (print): 1462-0324
ISSN (electronic): 1462-0332
Publisher: Oxford University Press
Altmetrics provided by Altmetric